Mary Porter, MD
Pulmonary Disease · Savannah, GANPI 1689642258
Payments from drug & device makers
Across 637 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$903
- Insmed, Inc.$572
- Boehringer Ingelheim$569
- Mylan Specialty L.p.$490
- plus $4K from 30 others
What the payments were for
- Food & beverage$11,75598%
- Education$2012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 129 | $2,973 |
| GSK | 161 | $2,159 |
| Regeneron Healthcare Solutions, Inc. | 42 | $903 |
| Insmed, Inc. | 36 | $572 |
| Boehringer Ingelheim | 36 | $569 |
| Mylan Specialty L.p. | 27 | $490 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $489 |
| Grifols USA, LLC | 22 | $405 |
| Sanofi | 17 | $394 |
| Axsome Therapeutics, Inc. | 13 | $284 |
| Amgen | 13 | $266 |
| Harmony Biosciences LLC | 9 | $241 |
| Actelion Pharmaceuticals US, Inc. | 11 | $224 |
| Verona Pharma, Inc. | 9 | $210 |
| Pulmonx Corporation | 5 | $204 |
| United Therapeutics Corporation | 9 | $178 |
| Jazz Pharmaceuticals Inc. | 9 | $175 |
| Mallinckrodt Hospital Products Inc. | 7 | $148 |
| Philips North America LLC | 8 | $145 |
| Electromed, Inc. | 11 | $115 |
| Inspire Medical Systems, Inc. | 4 | $112 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Sunovion Pharmaceuticals Inc. | 7 | $95 |
| Circassia Inc. | 5 | $67 |
| Merck | 4 | $67 |
| Hospira, Inc. | 3 | $57 |
| ANI Pharmaceuticals, Inc. | 3 | $54 |
| Genentech USA, Inc. | 3 | $45 |
| Pfizer | 2 | $43 |
| Vifor Pharma, Inc. | 2 | $35 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Shionogi Inc | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Viatris Specialty LLC | 1 | $14 |
| Fisher & Paykel Healthcare Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$343
- TEZSPIRE$237
- TRELEGY ELLIPTA$122
- AIRSUPRA$105
- FASENRA$105
How this compares
$11,956 in reported general payments places this provider in the 70th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 572 | $590,190 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 242 | $213,359 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $119,432 |
| Breo ElliptaFluticasone/Vilanterol | 206 | $111,160 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 145 | $84,658 |
| Ambrisentan | 29 | $52,274 |
| Spiriva RespimatTiotropium Bromide | 60 | $52,130 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 48 | $36,316 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 858 | $29,241 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $28,049 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $18,941 |
| EliquisApixaban | 26 | $18,208 |
| Roflumilast | 134 | $14,671 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $11,906 |
| Spiriva HandihalerTiotropium Bromide | 14 | $11,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $2,159 | $800,493955 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,973 | $241,408307 claims |
| Grifols USA, LLCProlastin C | $405 | $119,43213 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $569 | $107,387128 claims |
| PfizerEliquis | $43 | $18,20826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Savannah
- Lawrence McDermottSavannah$963K
- Michael MullinsSavannah$132K
- Michael PerkinsSavannah$67K
- Ryan MoodySavannah$50K
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.